Physician profile
Jamal Dixon
NPI 1427443118
$816.17
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $189 · 2021: $72.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $146.34 | 2019-2020 | |
| Astellas Pharma US INC | $124.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.56 | 2019-2020 | |
| Pfizer INC. | $58.47 | 2019-2020 | |
| Lilly USA, LLC | $55.98 | 2019 | |
| Novo Nordisk INC | $54.93 | 2019-2020 | |
| Alkermes, INC. | $41.59 | 2021 | |
| Merck Sharp & Dohme LLC | $38.42 | 2019 | |
| Lupin INC. | $29.36 | 2020 | |
| Genentech USA, INC. | $29.31 | 2019 | |
| Phadia US INC. | $25.55 | 2019 | |
| Glaxosmithkline, LLC. | $25.05 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $24.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.61 | 2019 | |
| Indivior INC. | $17.77 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $17.16 | 2020 | |
| Sanofi-Aventis U.S. LLC | $15.76 | 2019 | |
| Amgen INC. | $13.35 | 2019 | |
| Medtronic, INC. | $12.64 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.